Arienti C - Search Results

1

Role of Hyperbaric Oxygenation Plus Hypofractionated Stereotactic Radiotherapy in Recurrent High-Grade Glioma.

Arpa D, Parisi E, Ghigi G, Cortesi A, Longobardi P, Cenni P, Pieri M, Tontini L, Neri E, Micheletti S, Ghetti F, Monti M, Foca F, Tesei A, Arienti C, Sarnelli A, Martinelli G, Romeo A. Arpa D, et al. Among authors: arienti c. Front Oncol. 2021 Mar 30;11:643469. doi: 10.3389/fonc.2021.643469. eCollection 2021. Front Oncol. 2021. PMID: 33859944 Free PMC article.

2

Pro-apoptotic activity of cyclopentenone in cancer cells.

Rosetti M, Frasnelli M, Fabbri F, Arienti C, Vannini I, Tesei A, Zoli W, Conti M. Rosetti M, et al. Among authors: arienti c. Anticancer Res. 2008 Jan-Feb;28(1A):315-20. Anticancer Res. 2008. PMID: 18383863 Free article.

3

Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells.

Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, Ulivi P, Rosetti M, Vannini I, Arienti C, Zoli W, Silvestrini R. Fabbri F, et al. Among authors: arienti c. J Cell Physiol. 2008 Nov;217(2):494-501. doi: 10.1002/jcp.21522. J Cell Physiol. 2008. PMID: 18615564

4

Activity of lipoplatin in tumor and in normal cells in vitro.

Arienti C, Tesei A, Ravaioli A, Ratta M, Carloni S, Mangianti S, Ulivi P, Nicoletti S, Amadori D, Zoli W. Arienti C, et al. Anticancer Drugs. 2008 Nov;19(10):983-90. doi: 10.1097/CAD.0b013e3283114fb2. Anticancer Drugs. 2008. PMID: 18827563

5

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. Ulivi P, et al. Among authors: arienti c. J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753. J Cell Physiol. 2009. PMID: 19288493

6

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.

Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W. Tesei A, et al. Among authors: arienti c. J Cell Mol Med. 2011 Feb;15(2):316-26. doi: 10.1111/j.1582-4934.2009.00993.x. J Cell Mol Med. 2011. PMID: 20015197 Free PMC article.

7

Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus.

Fabbri F, Zoli W, Carloni S, Ulivi P, Arienti C, Brigliadori G, Montanari M, Tesei A, Silvestrini R, Amadori D. Fabbri F, et al. Among authors: arienti c. J Cell Physiol. 2011 Nov;226(11):3035-42. doi: 10.1002/jcp.22654. J Cell Physiol. 2011. PMID: 21302303

8

Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.

Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W. Arienti C, et al. J Transl Med. 2011 Jun 20;9:94. doi: 10.1186/1479-5876-9-94. J Transl Med. 2011. PMID: 21689426 Free PMC article.

9

Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.

Tesei A, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C, Sparatore A, Del Soldato P, Pasini A, Amadori D, Silvestrini R, Zoli W. Tesei A, et al. Among authors: arienti c. J Cell Physiol. 2012 Oct;227(10):3389-96. doi: 10.1002/jcp.24039. J Cell Physiol. 2012. PMID: 22212895

10

SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R, Zoli W. Arienti C, et al. Cell Oncol (Dordr). 2013 Apr;36(2):131-9. doi: 10.1007/s13402-012-0120-6. Epub 2012 Dec 19. Cell Oncol (Dordr). 2013. PMID: 23250725

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page